August 2017
Could a Cancer Drug Preserve Some Beta Cell Function in Those Newly Diagnosed With Type 1 Diabetes
An early research study suggests that imatinib, which is a drug that suppresses the immune system , may help to preserve some beta cell function in people who are recently diagnosed with Type 1 diabetes. Imatinib, a tyrosine kinase inhibitor, is already approved for use in the treatment of Chronic Myelogenous Leukemia (CML) and several other cancers.
Sneak Preview of New Type 1 Diabetes Research to be Presented at EASD Meeting
The European Association for the Study of Diabetes 2017 annual meeting will take place in Lisbon, Portugal from September 11-15, 2017. Some interesting research on Type 1 diabetes is on tap for the meeting, so here's a sneak preview!
Type 1 Diabetes Post Meal Insulin Dosing Leads to Poorer Glucose Control
Do you tend to bolus for your meal or snack during or after eating? If so, you may be unwittingly getting in your own way.
New Benefits Found With Liraglutide Use in Type 1 Diabetes Patients
Although it didn't work wonders for blood glucose (BG) levels, liraglutide improved anthropometric and metabolic parameters without causing an increase in hypoglycemia, according to the results of a clinical trial published in July in Diabetes, Obesity, and Metabolism.
Glucose Concentrations and A1c Levels Vary by Race
Have you ever noticed when you look at your lab results, there's a measure of kidney function called eGFR that is reported for both non-African American, and for African American? That's because there are racial and ethnic differences in kidney function decline. When it comes to A1c levels, they are higher in black people than in white people. It is debatable if this is because of poorer glycemic control, or whether there are, in fact, differences between the races in the glycation of hemoglobin.
Encouraging News About Sotagliflozin Use in Type 1 Diabetes
Sotagliflozin is a drug in development, under investigation by Lexicon Pharmaceuticals and Sanofi. It is a first-in-class, oral dual inhibitor of sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2).
Peptide Immunotherapy – New Promising Research
New research shows promise in keeping beta cell insulin production stable in those with newly diagnosed type 1 diabetes.
Trivia Time: August 2017 Type 1 Diabetes Trivia Question
Answer our type 1 diabetes trivia question and win a free book!
Our August 2017 Integrated Diabetes Services Survey
We'd like to know what you think! Participate in our Integrated Diabetes Services monthly survey.
ViaCyte Starts Clinical Trial on PEC-Direct Islet Cell Replacement Therapy
Wouldn't it be great if a commercially-available product existed that was derived from stem cells and could effectively replace pancreatic islet cells to allow folks who can't produce endogenous insulin to actually start making it? ViaCyte is working on turning this into a reality someday.